Men en anden praksis, der sigter mod at begrænse parallel handel, såsom et dobbeltprissystem - der, som De ved, er systemer, hvor priserne er forskellige, alt efter om produktet er til lokal brug eller til eksport til de andre medlemsstater - har man anset for at overtræde artikel 81, i f.eks. Glaxo-Wellcome-dommen fra maj 2001.
However, another type of practice aimed at curbing parallel trade such as ‘dual pricing systems’ – which, as you know, are systems where prices differ according to whether the product is for local consumption or for export to the other Member States – has been held to infringe Article 81 in, for example, the Glaxo-Wellcome decision of May 2001.